1[1]Huggins C, Scott W W. Bilateral adrenalectomy in prostatic cancer. Clinical features and urinary excretion of 17-ketosteroids and estrogen. Ann Surg , 1945, 122:1031-1041.
2[2]Bracci U. Antiandrogens in the treatment of prostatic cancer. Eur Urol, 1979, 5:303-306.
3[3]Soloaway M S, Schellhammer P, Sharifi R, et al. A controlled trial of CasodexTM (Bicalutamide) vs. Flutamide, each in combination with Luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Ure Urol, 1996, 29 (Ssuppl 2):105-109.
4[4]Szabo J, Bartok K, Keréni T,et al. Follow-up of prostate carcinoma patients treated with total androgen blockade by repeated map-biopsy. Ann Urol (Paris), 2000, 34:236-239.
5[5]Myers R B, Kudlow J E, Grizzle W E. Expression of transforming growth factor-alpha, epidermal growth factor and the epidermal growth factor receptor in adenocarcinoma of the prostate and benign prostatic hyperplasia. Mod Pathol,1993, 6:733-737.
6[6]Shiina H, Igawa M, Shigeno K, et al. Relationship of serum testosterone level with proliferating cell nuclear antigen and nm23 protein in human prostatic carcinoma tissue. Oncology, 1997, 54:482-489.
7[7]Taplin M E, Bubley G J, Ko Y J,et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res, 1999, 59:2511-2515.
8[8]Seidenfeld J, Samson D J, Hasselblad V, et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med, 2000, 132:566-577.
9[9]Dijkman G A, Janknegr R A, De Reyke T M, et al. Long-term efficacy and safety of Nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. J Urol, 1997, 158:160-163.
10[10]Crawford E D, Eisenberger M A, Mcleod D G, et al. A controlled trial of leuprolide with and without flutamide in prostate carcinoma. N Engl J Med, 1989, 321:419-424.
